Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Explore this paper's citation graph
Summary
Oral MPT is an effective first-line treatment for elderly patients with multiple myeloma and anticoagulant prophylaxis reduces frequency of thrombosis.
- Type
- article
- Published
- 2006-03-11
- Cited by
- 820
- References
- 36
- OpenAlex
- https://openalex.org/W2117172636
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:10918049
Keywords
Medicine, Thalidomide, Melphalan, Prednisone, Hazard ratio
References
- Management of thalidomide toxicity.
- Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
- Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
- Cancer and Venous Thromboembolism
- Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma.
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
- Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
- Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade.
- Thalidomide is an inhibitor of angiogenesis.
- Deep venous thrombosis and thalidomide therapy for multiple myeloma.
- The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma
- Common and rare side‐effects of low‐dose thalidomide in multiple myeloma: focus on the dose‐minimizing peripheral neuropathy
- Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma
- S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide.
- Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
- Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma
- Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production.
- Low-dose thalidomide in myeloma: efficacy and biologic significance.
- Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy.
- Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
Cited by
- Serum M‐spike and transplant outcome in patients with multiple myeloma
- Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma.
- Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
- Progress in multiple myeloma.
- Novel agents in myeloma: An exciting saga
- Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial
- Multiple myeloma: management of adverse events
- Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia
- The role of surgery for haematologic neoplasms of bone.
- Multiple myeloma: chemotherapy or transplantation in the era of new drugs
- Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma
- Novel drugs in myeloma: harnessing tumour biology to treat myeloma.
- Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
- Low molecular weight heparins for thromboprophylaxis during induction chemotherapy in patients with multiple myeloma.
- Effets antiangiogéniques dans le traitement des hémopathies malignes
- Diagnosis and the current trends in multiple myeloma therapy.
- Multiple myeloma in the elderly: when to treat, when to go to transplant.
- Current and Emerging Treatments for Multiple Myeloma
- Les nouveaux médicaments du myélome
- Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies.
Related papers
- Thalidomide combined with MP and VAD in the treatment of multiple myeloma for 42 cases
- Thalidomide in patients with advanced multiple myeloma.
- Unmaintained remissions in multiple myeloma.
- 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
- Low-dose thalidomide seems to be effective in multiple myeloma.
- Effectiveness of thalidomide for treating multiple myeloma in China:a meta-analysis
- The Current Status of Thalidomide in the Management of Multiple Myeloma
- Unmaintained remissions in multiple myeloma
- Thalidomide in multiple myeloma.
- Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma